Veronick Benoy

Leuven, VLG 3000, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.

Journal: Journal of medicinal chemistry

Published: April 08, 2021

Primary Active Ca2+ Transport Systems in Health and Disease.

Primary Active Ca2+ Transport Systems in Health and Disease.

Journal: Cold Spring Harbor perspectives in biology

Published: September 11, 2019

ATP13A2 deficiency disrupts lysosomal polyamine export.

ATP13A2 deficiency disrupts lysosomal polyamine export.

Journal: Nature

Published: December 21, 2018

Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.

Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.

Journal: ACS chemical neuroscience

Published: December 05, 2018

HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.

HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.

Journal: Brain : a journal of neurology

Published: June 13, 2017

Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.

Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: December 14, 2016

Defective axonal transport: A common pathological mechanism in inherited and acquired peripheral neuropathies.

Defective axonal transport: A common pathological mechanism in inherited and acquired peripheral neuropathies.

Journal: Neurobiology of disease

Published: December 07, 2016

HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients.

HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients.

Journal: Nature communications

Published: November 22, 2016

Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.

Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: September 02, 2016

Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors.

Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors.

Journal: Organic & biomolecular chemistry

Published: January 30, 2016

Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.

Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.

Journal: ACS chemical neuroscience

Published: November 25, 2015

Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.

Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.

Journal: Chemical communications (Cambridge, England)

Published: May 22, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026